Breaking News, Financial News

Financial Reports: Merck 2Q11

Sales up, but Merck announces major restructuring effort

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Merck 2Q11 2Q Revenues: $12.2 billion (+7%) 2Q Earnings: $2.0 billion (+169%) YTD Revenues: $23.7 billion (+4%) YTD Earnings: $3.1 billion (+181%) Comments: Sales growth in 2Q was driven by big jumps in Remicade (+26% to $842 million), Januvia (+30% to $779 million) and Janumet (+47% to $321 million), offsetting losses in Cozaar/Hyzaar (-16% to $406 million). Earnings took a big jump, due to restructuring charges in 2Q10. Singulair sales rose 8% to $1.4 billion during its last full year of ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters